Sore Throat News and Research

RSS

Pennsylvania Department of Health reports four confirmed and six probable cases of H3N2v flu

The Pennsylvania Department of Health today reported four confirmed and six probable human cases of influenza due to a new strain of the flu known as H3N2v.

18 Aug 2012

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.

18 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Be ‘medicinewise’ with cough and cold medicines in young children

NPS MedicineWise is urging parents and health professionals to heed the advice from the Therapeutic Goods Administration (TGA) this week restricting the use of cough and cold medicines to treat young children amidst concerns they have limited efficacy and may even be harmful.

16 Aug 2012

Heartburn and cancer: an interview with Mindy Mintz Mordecai

What most of us think of as heartburn is a symptom of Reflux Disease or GERD (Gastroesophageal Reflux Disease). It’s that burning discomfort an individual experiences when stomach acids and other fluids come back up into their esophagus.

14 Aug 2012

Heartburn can cause cancer: New guide for patients

Every day, an estimated 25 million American adults suffer from heartburn. Some experts believe that 40 percent of adults experience heartburn every month. Despite these staggering statistics, few people understand the real risk that Heartburn can cause Cancer.

6 Aug 2012

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

6 Aug 2012

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jul 2012

Fatal outcome from HFMD is rare, says LUHS pediatric infectious disease specialist

A mysterious disease that has killed nearly 60 children in Cambodia has been identified by the World Health Organization as enterovirus 71. This virus is one among a family of viruses that cause a variety of illnesses, including a common childhood illness called hand, foot and mouth disease, but Andrew Bonwit, MD, pediatric infectious disease specialist at Loyola University Health System, says a fatal outcome from such illness is rare.

11 Jul 2012

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

30 May 2012

European CHMP issues positive opinion to Vertex's KALYDECO for treatment of CF

Vertex Pharmaceuticals Incorporated announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion by consensus recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

25 May 2012

Linagliptin safe and effective for African American patients with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.

25 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

AstraZeneca introduces DUTOPROL for hypertension

AstraZeneca today announced the availability of DUTOPROL (metoprolol succinate extended release/hydrochlorothiazide) Tablets, the first and only once-daily antihypertensive agent that contains the active ingredient of TOPROL-XL (metoprolol succinate) plus a low-dose diuretic that provides proven blood pressure lowering at 24 hours.

12 Apr 2012

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

MedImmune receives FDA approval for FluMist Quadrivalent vaccine

FluMist Quadrivalent, a vaccine to prevent seasonal influenza in people ages 2 years through 49 years, has been approved today by the U.S. Food and Drug Administration. FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus, two influenza A strains and two influenza B strains.

27 Mar 2012

Valeant signs agreement to acquire Natur Produkt

Valeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire Natur Produkt International, JSC, a specialty pharmaceutical company in Russia.

26 Mar 2012

Air emissions near natural gas drilling sites may contribute to health problems

In a new study, researchers from the Colorado School of Public Health have shown that air pollution caused by hydraulic fracturing or fracking may contribute to acute and chronic health problems for those living near natural gas drilling sites.

19 Mar 2012

Study examines how symptoms presented online influence people's reactions to medical conditions

Maybe you've had a reoccurring sore throat or frequent headaches. Perhaps the pain in your leg won't go away. In the past, you might have gone to a doctor's office to diagnose symptoms.

13 Mar 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

Sore Throat News and Research

Pennsylvania Department of Health reports four confirmed and six probable cases of H3N2v flu

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Be ‘medicinewise’ with cough and cold medicines in young children

Heartburn and cancer: an interview with Mindy Mintz Mordecai

Heartburn can cause cancer: New guide for patients

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Fatal outcome from HFMD is rare, says LUHS pediatric infectious disease specialist

Corrected interim data from Vertex VX-809, KALYDECO combination Phase 2 study for CF

European CHMP issues positive opinion to Vertex's KALYDECO for treatment of CF

Linagliptin safe and effective for African American patients with type 2 diabetes

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

AstraZeneca introduces DUTOPROL for hypertension

Needle-free vaccine shows promise against RSV in children

MedImmune receives FDA approval for FluMist Quadrivalent vaccine

Valeant signs agreement to acquire Natur Produkt

Air emissions near natural gas drilling sites may contribute to health problems

Study examines how symptoms presented online influence people's reactions to medical conditions

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News